{"id":"v116","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"V116 binds to conserved epitopes on the surface of group B Streptococcus, promoting opsonophagocytosis and complement-mediated killing. By enhancing the immune system's ability to recognize and eliminate GBS, the vaccine aims to prevent invasive GBS disease, particularly in pregnant women and neonates.","oneSentence":"V116 is a monoclonal antibody that targets group B Streptococcus (GBS) to enhance immune recognition and clearance of the pathogen.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:53:55.047Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of group B Streptococcus (GBS) disease in pregnant women and neonates"}]},"trialDetails":[{"nctId":"NCT06177912","phase":"PHASE3","title":"A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-18","conditions":"Pneumococcal Infection","enrollment":882},{"nctId":"NCT05696080","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-13","conditions":"Pneumococcal Infection","enrollment":518},{"nctId":"NCT05569954","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-11-07","conditions":"Pneumococcal Disease","enrollment":1484},{"nctId":"NCT05393037","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-13","conditions":"Pneumococcal Disease","enrollment":313},{"nctId":"NCT05526716","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly With Influenza Vaccine in Adults 50 Years of Age or Older (V116-005, STRIDE-5)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-09-23","conditions":"Pneumonia, Pneumococcal","enrollment":1080},{"nctId":"NCT05425732","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-13","conditions":"Pneumococcal Infection","enrollment":2663},{"nctId":"NCT05420961","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-07-12","conditions":"Pneumonia, Pneumococcal","enrollment":717},{"nctId":"NCT05633992","phase":"PHASE3","title":"Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-01-10","conditions":"Pneumococcal Disease","enrollment":450},{"nctId":"NCT05464420","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-08-12","conditions":"Pneumococcal Disease","enrollment":2162},{"nctId":"NCT04665050","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-04","conditions":"Pneumococcal Infection","enrollment":102},{"nctId":"NCT04168190","phase":"PHASE1, PHASE2","title":"A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-06","conditions":"Pneumonia, Pneumococcal","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":41,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Polyvalent pneumococcal conjugate vaccine (pPCV)","Pneumococcal 21-valent Conjugate Vaccine"],"phase":"phase_3","status":"active","brandName":"V116","genericName":"V116","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"V116 is a monoclonal antibody that targets group B Streptococcus (GBS) to enhance immune recognition and clearance of the pathogen. Used for Prevention of group B Streptococcus (GBS) disease in pregnant women and neonates.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}